BioMarin breaks out positive PhII achondroplasia data; Thermo Fisher opens 'customer solutions' facility in China
→ After recently handing off its rare disease drug to Allievex, BioMarin provided an update on its ongoing Phase II study of vosoritide in children with achondroplasia. The study showed that in “over 54 months, children in cohort 3 (N=10) of the study, at a dose of 15 µg/kg/day, achieved a statistically significant (p< 0.005) cumulative additional mean height gain of 9 cm compared to children, matched for age and gender, in a new natural history achondroplasia dataset (N=619).” The company plans to release the data from its Phase III study by the end of the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
